Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Lupin Limited    LUPIN   INE326A01037

End-of-day quote. End-of-day quote  - 08/18
937.85 INR   -1.58%
07/24 LUPIN LIMITED : ex-dividend day for annual dividend
05/31 Novartis CEO sees no need for big takeover
05/19LUPIN LIMITED : annual earnings release
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Lupin Limited : Lupin Looking for Acquisitions of up to $500 Million in US

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/01/2012 | 06:39am EDT

--Looking for buys in skin care, eye care, respiratory and women's health products

--Trying to expand pipeline of low-competition generic drugs for US market

(Adds executive's comments in 7th, 9th, 12th and 13th paragraphs, background and context elsewhere)

By Rumman Ahmed

BANGALORE--Lupin Ltd. (500257.BY) is looking to aggressively grow its business in the U.S. and is scouting for acquisitions of pharmaceutical brands and manufacturers, and seeking regulatory approval to sell a wider range of niche generic drugs.

The U.S. is Lupin's primary growth market, accounting for 35% of its sales.

The India drug maker is benefiting from a wave of patent expiries for popular drugs in the U.S. But to keep the business momentum going once the "patent cliff" wave wanes, Lupin is looking to acquire branded products that are much bigger that its previous purchases.

"We've looked at small-sized acquisition opportunities as well as opportunities in the $400 million-$500 million price range," group president Vineeta Gupta recently told Dow Jones Newswires.

Unlike most of its local rivals, Lupin's business model for the world's largest pharmaceuticals market is not limited to selling drug copies: It also sells branded products like antibiotic Suprax and anti-cholesterol drug Antara. While the branded products contribute about 25% of Lupin's U.S. revenue, they make up a larger share of its profit.

Lupin is looking for acquisitions to revive the momentum in the branded-products business at a time when existing brands are likely to come up against generic competition.

The company would prefer acquisitions in the areas of skin care, eye care, respiratory and women's health products, which are more in line with the company's commercial infrastructure in the U.S., Ms. Gupta said.

The company's 160-person sales force in the U.S. is focused on selling branded products to the pediatric and primary-care market segments.

Ms. Gupta, who also heads Lupin's U.S. unit, said Lupin had mulled acquiring eye-care company ISTA Pharmaceuticals Inc., but found it wasn't a "good fit."

Eye-products maker Bausch & Lomb Inc. purchased ISTA for about $500 million in cash in a deal that closed in June.

Lupin's previous acquisitions in the U.S. were much smaller in comparison. In 2009 it paid $38.61 million to bankrupt Oscient Pharmaceuticals Corp. for Antara, and acquired AllerNaze nasal spray from U.S.-based Collegium Pharmaceutical Inc. for an undisclosed amount.

As for its generic drugs business, Lupin is trying to move its pipeline to products that are exclusive and face less competition, Ms. Gupta said.

Lupin has already applied to sell generic versions of about 31 oral contraceptive products and some eye treatments. It has also filed the first generic drug application with the U.S. regulator for a skin care product in the January-March period, she added.

Benefits from selling these drugs, which have relatively high entry barriers and offer higher-than-average margins, are expected to kick in from the fiscal year starting next April.

Write to Rumman Ahmed at rumman.ahmed@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LUPIN LIMITED
08/10 LUPIN : receives USFDA nod for cholesterol drug
08/09 LUPIN : Zydus receive nod from us fda for two drugs
08/09 LUPIN : Eyes speciality businesses in us
08/09 LUPIN : receives USFDA approval for Nikita (Pitavastatin) tablets
08/04 LUPIN : gets USFDA nod to market Rosuvastatin Calcium
08/03 LUPIN : Q1 PROFIT DIPS 59% TO Rs358 CRORE
07/30 LUPIN : USFDA clears Lupin’s Pithampur manufacturing unit inspection
07/29 India shares lower at close of trade; Nifty 50 down 0.06%
07/25 LUPIN : receives US FDA approval for anti-inflammatory topical solution
07/24 LUPIN : gets USFDA nod for Fluocinonide Topical Solution
More news
Financials ( INR)
Sales 2018 170 095 M
EBIT 2018 29 082 M
Net income 2018 21 000 M
Debt 2018 44 047 M
Yield 2018 0,80%
P/E ratio 2018 20,14
P/E ratio 2019 15,84
EV / Sales 2018 2,75x
EV / Sales 2019 2,37x
Capitalization 423 898 M
Chart LUPIN LIMITED
Duration : Period :
Lupin Limited Technical Analysis Chart | LUPIN | INE326A01037 | 4-Traders
Technical analysis trends LUPIN LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 43
Average target price 1 150  INR
Spread / Average Target 23%
EPS Revisions
Managers
NameTitle
Nilesh Deshbandhu Gupta Managing Director & Executive Director
Vinita D. Gupta Chief Executive Officer & Executive Director
Manju Deshbandu Gupta Chairman
Ramesh Swaminathan Chief Financial Officer & Executive Director
Alok Ghosh President-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
LUPIN LIMITED-36.78%6 608
JOHNSON & JOHNSON15.12%355 979
NOVARTIS7.69%216 915
ROCHE HOLDING LTD.3.78%216 699
PFIZER0.59%194 554
MERCK AND COMPANY4.45%167 705